Invention Grant
- Patent Title: Native human antibodies for immune checkpoint modulation targets TIM-3 and B7-H3
-
Application No.: US15861410Application Date: 2018-01-03
-
Publication No.: US11046764B2Publication Date: 2021-06-29
- Inventor: Angeles Estelles , Mikhail Gishizky , Stefan Ryser , Lawrence M. Kauvar
- Applicant: Trellis Bioscience, LLC
- Applicant Address: US CA Menlo Park
- Assignee: Trellis Bioscience, LLC
- Current Assignee: Trellis Bioscience, LLC
- Current Assignee Address: US CA Menlo Park
- Agency: FisherBroyles, LLP
- Agent Victoria L. Boyd; Frank W. Leak
- Main IPC: C07K16/00
- IPC: C07K16/00 ; C07K16/28 ; C07K16/30 ; A61P35/00
Abstract:
Novel monoclonal antibodies directed against immune checkpoint modulator (ICM) proteins TIM-3 and B7-H3 are useful in treating cancer and immune system disorders.
Public/Granted literature
- US20180186880A1 NATIVE HUMAN ANTIBODIES FOR IMMUNE CHECKPOINT MODULATION TARGETS TIM-3 AND B7-H3 Public/Granted day:2018-07-05
Information query
